Identification of a germline deep intronic PTEN-deletion leading to exonization through whole genome and targeted RNA sequencing
- PMID: 39920402
- DOI: 10.1007/s10689-025-00445-z
Identification of a germline deep intronic PTEN-deletion leading to exonization through whole genome and targeted RNA sequencing
Abstract
PTEN Hamartoma Tumor Syndrome (PHTS) is an autosomal dominant disorder characterized by high penetrance and significant phenotypic variability. In most patients, targeted high-throughput sequencing (HTS) approaches enable the detection of loss-of-function pathogenic variants in PTEN, a tumor suppressor gene acting as a negative regulator of the PI3K-AKT pathway. We describe a patient exhibiting a clinical phenotype strongly indicative of PHTS, yet lacking a molecular diagnosis through PTEN-targeted HTS. After several years of diagnostic uncertainty, trio whole genome sequencing (WGS) ultimately identified a de novo germline deep intronic 98 bp deletion in PTEN intron 5 (c.492 + 1671_492 + 1768del). Targeted RNA sequencing revealed the inclusion of a pseudoexon, resulting in a frameshift and predicted protein truncation at codon 171 (p.Val166Asnfs*6). These data underline the importance of WGS approaches in detecting deep intronic structural variants, that may be overlooked by conventional methods.
Keywords: Deep intronic variants; PTEN; PTEN Hemartoma Tumor Syndrome; Whole genome sequencing.
© 2025. The Author(s), under exclusive licence to Springer Nature B.V.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethical approval: We present a case report of a patient followed at Strasbourg University Hospital. Genome sequencing was performed as part of the France Genomic Medicine Plan 2025 (PFMG2025), and the family was selected during a national multidisciplinary consultation meeting. All data were collected during routine clinical care, with no additional exams conducted specifically for this study. Samples were obtained as part of standard care, with patients providing informed consent for the research use of their samples, in accordance with the guidelines of the institutional boards of Strasbourg University Hospital and PFMG2025, as well as the principles of the Declaration of Helsinki. Informed consent: Written informed consent was obtained from the patient in compliance with French law governing diagnostic genetic testing. Clinical and genetic samples were collected as part of standard care, with the patient’s explicit consent for the use of their data for research purposes.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials